faa glp 1 glp-1 The has approved certain weight loss medications, including GLP-1s. But approval is Pilots and Semaglutide: Navigating FAA

Second, 775+ adverse events have been reported involving compounded GLP-1 drugs

Important safety considerations include: Risk of acute pancreatitis: urgent medical review needed for severe, persistent abdominal pain (with or without back pain) Gallbladder disorders: seek medical advice for symptoms of gallstones (right upper abdominal pain, nausea) Diabetic retinopathy complications: particularly with semaglutide in those with pre-existing retinopathy Hypoglycaemia: risk is low unless combined with insulin or sulfonylureas, which may require dose adjustment Reports of mood changes and suicidal ideation in patients taking GLP-1 receptor agonists are being monitored by regulatory authorities

Prevents fat accumulation by inhibiting lipogenesis, making it harder for the body to store excess fat

In sum, current evidence positions GLP-1 RAs as a potential cardioprotective strategy in HF, with HF with preserved ejection fraction emerging as the clinically most relevant phenotype for the drug class, especially when occurring in people with obesity with and without diabetes